Risk Management



Compounded Drugs and Off-Label Use

Welcome to OMIC’s Compounded Drugs and Off-Label Use risk management resource library. We are committed to providing you with the resources and templates necessary to adequately inform your patients about the risks, benefits, and alternatives of this procedure.

Compounded Products: Use, Regulation, and Risk
Liability and Coverage for Contaminated-Product Claims
Reduce the Risks of Compounded Drugs
Read the Label Carefully: How Ads for Off-Label Drugs and Devices Could Harm Your Practice
Hotline Q&A: Standing Order Medications
Medical Implications of Using Off-Label Drugs and Devices
Case Study: Lack of Informed Consent for Use of a Research Drug
Informed Consent for Off-Label Use of a Drug or Device
When FDA Leaves Doctors to Their Own Devices
Responding to “Dear Healthcare Provider” Letters

2013 Update: New Regulations For Compounding Drugs Coming Into Focus…

Visit OMIC’s Drugs and Devices library to view other resources for Compounded Drugs and Off-Label Use including risk management articles, closed claim studies, and recommendation and procedure guides.

See also: Advertising resources.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



pie

Six reasons OMIC is the best choice for ophthalmologists in America.

#1. Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $20 Million to our members through dividends.

61864684